{"id":939,"date":"2021-04-07T10:18:33","date_gmt":"2021-04-07T10:18:33","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=939"},"modified":"2021-04-07T10:18:33","modified_gmt":"2021-04-07T10:18:33","slug":"30-mar-2021-ivermectin-improved-the-clinical-state-even-in-the-presence-of-comorbidities","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/30-mar-2021-ivermectin-improved-the-clinical-state-even-in-the-presence-of-comorbidities\/","title":{"rendered":"(30 Mar 2021) Ivermectin- improved the clinical state even in the presence of comorbidities"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p id=\"page-title\" class=\"highwire-cite-title\">IVERMECTIN REPROPOSING FOR COVID-19 TREATMENT OUTPATIENTS IN MILD STAGE IN PRIMARY HEALTH CARE CENTERS<\/p>\n<p class=\"\">https:\/\/www.medrxiv.org\/content\/10.1101\/2021.03.29.21254554v1<\/p>\n<p class=\"\">NCT04784481- A significant reduction in the symptom numbers was observed in the EG when the medical examination was performed from 5<sup>th<\/sup>&nbsp;to 9<sup>th<\/sup>&nbsp;days, after starting treatment (<em>p<\/em>&nbsp;= 0\u00b70026). Although, medical examination from 10<sup>th<\/sup>&nbsp;to 14<sup>th<\/sup>&nbsp;day, showed a progressive reduction of the percentage symptom numbers, these were not significative in both groups. A higher proportion of medical release was observed in EG (98\u00b72%) vs CG (87\u00b71%) (<em>p<\/em>&nbsp;= 0\u00b7003). EG showed 8 times more chance of receiving medical release than CG (OR 7\u00b799, 95% CI: 1\u00b764 \u221238\u00b797,&nbsp;<em>p<\/em>&nbsp;= 0\u00b7003). The treatment effect with ivermectin to obtain medical release was analyzed by the logistic regression model based in the following control variables: sex, age, and comorbidities. Then, the chance to obtain medical release was maintained in EG (OR 10\u00b737, 95% CI: 2\u00b705 &#8211; 52\u00b704,&nbsp;<em>p<\/em> = 0\u00b7005). Treatment with ivermectin in outpatients with mild stage COVID-19 disease managed to slightly reduce the symptom numbers. Also, this treatment improved the clinical state to obtain medical release, even in the presence of comorbidities.&nbsp;<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>IVERMECTIN REPROPOSING FOR COVID-19 TREATMENT OUTPATIENTS IN MILD STAGE IN PRIMARY HEALTH CARE CENTERS https:\/\/www.medrxiv.org\/content\/10.1101\/2021.03.29.21254554v1 NCT04784481- A significant reduction in the symptom numbers was observed in the EG when the medical examination was performed from 5th&nbsp;to 9th&nbsp;days, after starting treatment&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/30-mar-2021-ivermectin-improved-the-clinical-state-even-in-the-presence-of-comorbidities\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(30 Mar 2021) Ivermectin- improved the clinical state even in the presence of comorbidities&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[6,4,16],"tags":[38],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/939"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=939"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/939\/revisions"}],"predecessor-version":[{"id":940,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/939\/revisions\/940"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=939"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=939"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=939"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}